← Leaderboards
Danyang Chen
Charlesson, Llp
$3,659,618
Attributed
$4,014,736
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2007–16$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$4,014,736 · 9
By mechanism
R44$2,335,716 · 2
R43$1,679,020 · 7
Top collaborators
- Phillip Vanlandingham1 shared
Most similar at Charlesson, Llp
Same institution · by research overlap
- Kangmo Lu$1,672,720
- Rafal A Farjo$4,717,138
- Phillip Vanlandingham$355,119
Others in their field
Top investigators on “Vascular Endothelial Growth Factors”
- Keri Hammel · The Emmes Company, Llc$41,089,609
- Michael Simons · Yale University$37,207,792
- Norman Wolmark · Nsabp Foundation, Inc.$27,593,122
- Shahin Rafii · Weill Medical College Of Cornell Univ$24,406,332
- Rakesh K. Jain · Massachusetts General Hospital$23,479,897
- Aleksander S. Popel · Johns Hopkins University$19,039,579
Research focus
Vascular Endothelial Growth FactorsRattusPlayDrug KineticsBlindnessBlood VesselsRetinalRetinaExtravasationPharmaceutical PreparationsVisionSignal TransductionDiabetic RetinopathySeriesSolidInflammationInhibitor/AntagonistTumor Necrosis Factor-AlphaPathogenesisBaseNeovascularizationIntercellular Adhesion Molecule 1Vascular PermeabilitiesPathway Interactions
Grant awards (11)
Developing A Novel Therapy for Diabetic Retinopathy$710,237
R44 · FY2016 · EY · contact PI
Developing A Novel Therapy for Diabetic Retinopathy$785,308
R44 · FY2015 · EY · contact PI
A Novel Therapeutic Antibody for Age-related Macular Degeneration$225,000
R43 · FY2015 · EY · contact PI
A Wnt Modulator for Treatment of Age-related Macular Degeneration$225,000
R43 · FY2014 · EY · contact PI
Developing A Novel Therapy for Diabetic Retinopathy$246,418
R43 · FY2013 · EY · contact PI
A Small Molecule Targeting Wnt Pathway for Treatment of Diabetic Retinopathy$231,087
R43 · FY2012 · EY · contact PI
Multitargeted Therapy for Age-related Macular Degeneration$265,992
R43 · FY2011 · EY · contact PI
Novel Antioxidants for Treatment of Diabetic Retinopathy$248,094
R43 · FY2009 · EY · contact PI
A Novel Thalidomide Analog for the Treatment of Diabetic Macular Edema$390,326
R44 · FY2008 · EY · contact PI
A Novel Thalidomide Analog for the Treatment of Diabetic Macular Edema$449,845
R44 · FY2007 · EY · contact PI
Novel Combretastatin A4 analogs for Treatment of Retinal Neovascularization$237,429
R43 · FY2007 · EY · contact PI